Corneal Endothelial Dystrophy
7
1
1
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
14%
1 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (7)
Study to Assess Safety and Tolerability of Multiple Doses of EO2002
Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema
Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection
A Safety and Efficacy Trial of TTHX1114 in People With CED
A Phase 1/ Phase 2 Study of TTHX1114(NM141)
Phase 1 Study to Evaluate the Safety and Tolerability of EO1404 in the Treatment of Corneal Edema
Ripasudil 0.4% Eye Drops in Fuchs Endothelial Corneal Dystrophy